TD Cowen Boosts Insulet (NASDAQ:PODD) Price Target to $324.00

Insulet (NASDAQ:PODD) had its target price increased by investment analysts at TD Cowen from $264.00 to $324.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. TD Cowen’s target price indicates a potential upside of 21.67% from the company’s current price.

PODD has been the topic of a number of other reports. Morgan Stanley raised their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Sanford C. Bernstein began coverage on Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. JPMorgan Chase & Co. increased their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Citigroup boosted their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group lifted their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $272.81.

Insulet Stock Up 3.7 %

PODD stock opened at $266.30 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The firm has a market capitalization of $18.68 billion, a price-to-earnings ratio of 45.60, a PEG ratio of 4.12 and a beta of 1.21. The company’s 50 day moving average price is $260.30 and its 200 day moving average price is $227.97.

Insider Transactions at Insulet

In other news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. increased its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Insulet during the second quarter worth $32,000. Venturi Wealth Management LLC boosted its holdings in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the period. TD Private Client Wealth LLC boosted its stake in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the period. Finally, Versant Capital Management Inc lifted its position in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after acquiring an additional 157 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.